Speaker
Bruno Canard
(Laboratoire AFMB, CNRS et Aix-Mareille Université, France)
Description
Understanding how the CoV replication/transcription complex (RTC) works is central to design antiviral drug therapies as well as to the understanding of the emergence of variants. The SARS-CoV2 RTC is blatantly more 'active' than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of mispaired nucleotides ('errors') but also nucleotide analogues used as antiviral drugs.
Primary author
Bruno Canard
(Laboratoire AFMB, CNRS et Aix-Mareille Université, France)
